Global patterns of genetic diversity and signals of natural selection for human ADME genes

Human Molecular Genetics

Volumn 20, Issue 3, 2011, Pages 528-540

  Li, Jing ^a,b,c   Zhang, Luyong ^b   Zhou, Hang ^a   Stoneking, Mark ^c   Tang, Kun ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c MAX PLANCK INSTITUTE FOR EVOLUTIONARY ANTHROPOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION DISTRIBUTION METABOLISM AND EXCRETION GENE; ALLELE; ARTICLE; DRUG RESPONSE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ABSORPTION; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VARIATION; GEOGRAPHY; GLUTATHIONE TRANSFERASE; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 78651076990     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq498     Document Type: Article

References (83)

1. Grossman, I. (2007) Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics, 8, 1449-1459.
2. Lazarou, J., Pomeranz, B.H. and Corey, P.N. (1998) Incidence of adverse drug reactions in hospitalized patients-a meta-analysis of prospective studies. JAMA, 279, 1200-1205.
3. Fuhr, U., Jetter, A. and Kirchheiner, J. (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin. Pharmacol. Therapeut., 81, 270-283.
4. Daly, T.M., Dumaual, C.M., Miao, X., Farmen, M.W., Njau, R.K., Fu, D.J., Bauer, N.L., Close, S., Watanabe, N., Bruckner, C. et al. (2007) Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin. Chem., 53, 1222-1230.
5. Tetko, I.V., Bruneau, P., Mewes, H.W., Rohrer, D.C. and Poda, G.I. (2006) Can we estimate the accuracy of ADME-Tox predictions? Drug Discov. Today, 11, 700-707.
6. Balani, S.K., Miwa, G.T., Gan, L.S., Wu, J.T. and Lee, F.W. (2005) Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr. Top. Med. Chem., 5, 1033-1038.
7. Benet, L.Z. (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 6, 1631-1643.
8. Ma, M.K., Woo, M.H. and McLeod, H.L. (2002) Genetic basis of drug metabolism. Am. J. Health Syst. Pharm., 59, 2061-2069.
9. Karazniewicz-Lada, M., Luczak, M. and Glowka, F. (2009) Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica, 39, 476-485.
10. Stevens, J.C., Marsh, S.A., Zaya, M.J., Regina, K.J., Divakaran, K., Le, M. and Hines, R.N. (2008) Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos., 36, 1587-1593.
11. Nebert, D.W. (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet., 60, 265-271.
12. Coutts, R.T. (1994) Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J. Psychiatry Neurosci., 19, 30-44.
13. Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., Walker, J.R., Antman, E.M., Macias, W., Braunwald, E. et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 360, 354-362.
14. Ingelman-Sundberg, M. (2002) Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology, 181-182, 447-452.
15. Zhou, S.F., Liu, J.P. and Chowbay, B. (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 41, 89-295.
16. Ada, A.O., Suzen, S.H. and Iscan, M. (2004) Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population. Toxicol. Lett., 151, 311-315.
17. Magalon, H., Patin, E., Austerlitz, F., Hegay, T., Aldashev, A., Quintana-Murci, L. and Heyer, E. (2008) Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur. J. Hum. Genet., 16, 243-251.
18. Gardiner, S.J. and Begg, E.J. (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev., 58, 521-590.
19. Li, J.Z., Absher, D.M., Tang, H., Southwick, A.M., Casto, A.M., Ramachandran, S., Cann, H.M., Barsh, G.S., Feldman, M., Cavalli-Sforza, L.L. et al. (2008) Worldwide human relationships inferred from genome-wide patterns of variation. Science, 319, 1100-1104.
20. Hunley, K.L., Healy, M.E. and Long, J.C. (2009) The global pattern of gene identity variation reveals a history of long-range migrations, bottlenecks, and local mate exchange: implications for biological race. Am. J. Phys. Anthropol., 139, 35-46.
21. Lopez Herraez, D., Bauchet, M., Tang, K., Theunert, C., Pugach, I., Li, J., Nandineni, M.R., Gross, A., Scholz, M. and Stoneking, M. (2009) Genetic variation and recent positive selection in worldwide human populations: evidence from nearly 1 million SNPs. PLoS ONE, 4, e7888.
22. Cadamuro, J., Dieplinger, B., Felder, T., Kedenko, I., Mueller, T., Haltmayer, M., Patsch, W. and Oberkofler, H. (2009) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur. J. Clin. Pharmacol., 66, 236-260.
23. Lee, S.J., Kim, W.Y., Kim, H., Shon, J.H., Lee, S.S. and Shin, J.G. (2009) Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab. Dispos., 37, 2262-2269.
24. Marsh, S. and Van Booven, D.J. (2009) The increasing complexity of mercaptopurine pharmacogenomics. Clin. Pharmacol. Ther., 85, 139-141.
25. Wilson, J.F., Weale, M.E., Smith, A.C., Gratrix, F., Fletcher, B., Thomas, M.G., Bradman, N. and Goldstein, D.B. (2001) Population genetic structure of variable drug response. Nat. Genet., 29, 265-269.
26. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. and Fuselli, S. (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics, 17, 93-101.
27. Sistonen, J., Fuselli, S., Palo, J.U., Chauhan, N., Padh, H. and Sajantila, A. (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics, 19, 170-179.
28. Pasanen, M.K., Neuvonen, P.J. and Niemi, M. (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics, 9, 19-33.
29. Man, M., Farmen, M., Dumaual, C., Teng, C.H., Moser, B., Irie, S., Noh, G.J., Njau, R., Close, S., Wise, S. et al. (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharmacol, 8, 929-940.
30. Nielsen, R., Hellmann, I., Hubisz, M., Bustamante, C. and Clark, A.G. (2007) Recent and ongoing selection in the human genome. Nat. Rev. Genet., 8, 857-868.
31. Hesselson, S.E., Matsson, P., Shima, J.E., Fukushima, H., Yee, S.W., Kobayashi, Y., Gow, J.M., Ha, C., Ma, B., Poon, A. et al. (2009) Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS ONE, 4, e6942.
32. Thompson, E.E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B.A. and Di Rienzo, A. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet., 75, 1059-1069.
33. Voight, B.F., Kudaravalli, S., Wen, X. and Pritchard, J.K. (2006) A map of recent positive selection in the human genome. PLoS Biol., 4, e72.
34. Patin, E., Harmant, C., Kidd, K.K., Kidd, J., Froment, A., Mehdi, S.Q., Sica, L., Heyer, E. and Quintana-Murci, L. (2006) Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum. Mutat., 27, 720.
35. Luca, F., Bubba, G., Basile, M., Brdicka, R., Michalodimitrakis, E., Rickards, O., Vershubsky, G., Quintana-Murci, L., Kozlov, A.I. and Novelletto, A. (2008) Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS ONE, 3, e3136.
36. Sun, C., Southard, C., Witonsky, D.B., Kittler, R. and Rienzo, A.D. (2010) Allele-Specific Down-Regulation of RPTOR Expression Induced by Retinoids Contributes to Climate Adaptations. PLoS Genet., 6, e1001178.
37. Altshuler, D.M., Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., Bonnen, P.E., de Bakker, P.I., Deloukas, P., Gabriel, S.B. et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature, 467, 52-58.
38. Dumaual, C., Miao, X., Daly, T.M., Bruckner, C., Njau, R., Fu, D.J., Close-Kirkwood, S., Bauer, N., Watanabe, N., Hardenbol, P. et al. (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix (R) Targeted Genotyping System. Pharmacogenomics, 8, 293-305.
39. Coulombe-Huntington, J., Lam, K.C., Dias, C. and Majewski, J. (2009) Fine-scale variation and genetic determinants of alternative splicing across individuals. PLoS Genet., 5, e1000766.
40. Barendse, W., Harrison, B.E., Bunch, R.J., Thomas, M.B. and Turner, L.B. (2009) Genome wide signatures of positive selection: the comparison of independent samples and the identification of regions associated to traits. BMC Genomics, 10, 178.
41. Coop, G., Pickrell, J.K., Novembre, J., Kudaravalli, S., Li, J., Absher, D., Myers, R.M., Cavalli-Sforza, L.L., Feldman, M.W. and Pritchard, J.K. (2009) The role of geography in human adaptation. PLoS Genet., 5, e1000500.
42. Tang, K., Thornton, K.R. and Stoneking, M. (2007) A new approach for using genome scans to detect recent positive selection in the human genome. PLoS Biol., 5, e171.
43. Pickrell, J.K., Coop, G., Novembre, J., Kudaravalli, S., Li, J.Z., Absher, D., Srinivasan, B.S., Barsh, G.S., Myers, R.M., Feldman, M.W. et al. (2009) Signals of recent positive selection in a worldwide sample of human populations. Genome Res., 19, 826-837.
44. Nielsen, R. (2005) Molecular signatures of natural selection. Annu. Rev. Genet., 39, 197-218.
45. van der Weide, J. and Steijns, L.S. (1999) Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann. Clin. Biochem., 36, 722-729.
46. Lai, J., Vesprini, D., Chu, W., Jernstrom, H. and Narod, S.A. (2001) CYP gene polymorphisms and early menarche. Mol. Genet. Metab., 74, 449-457.
47. Thier, R., Bruning, T., Roos, P.H., Rihs, H.P., Golka, K., Ko, Y. and Bolt, H.M. (2003) Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int. J. Hyg. Environ. Health, 206, 149-171.
48. Qiu, H., Taudien, S., Herlyn, H., Schmitz, J., Zhou, Y., Chen, G., Roberto, R., Rocchi, M., Platzer, M. and Wojnowski, L. (2008) CYP3 phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7. Pharmacogenet. Genomics, 18, 53-66.
49. Chen, X., Wang, H., Zhou, G., Zhang, X., Dong, X., Zhi, L., Jin, L. and He, F. (2009) Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine. Environ. Health Perspect., 117, 1541-1548.
50. Momary, K.M., Shapiro, N.L., Viana, M.A., Nutescu, E.A., Helgason, C.M. and Cavallari, L.H. (2007) Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics, 8, 1535-1544.
51. Leschziner, G.D., Andrew, T., Pirmohamed, M. and Johnson, M.R. (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J., 7, 154-179.
52. Tang, K., Ngoi, S.M., Gwee, P.C., Chua, J.M., Lee, E.J., Chong, S.S. and Lee, C.G. (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics, 12, 437-450.
53. Tang, K., Wong, L.P., Lee, E.J., Chong, S.S. and Lee, C.G. (2004) Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet., 13, 783-797.
54. Mamanova, L., Coffey, A.J., Scott, C.E., Kozarewa, I., Turner, E.H., Kumar, A., Howard, E., Shendure, J. and Turner, D.J. (2010) Target-enrichment strategies for next-generation sequencing. Nat. Methods, 7, 111-118.
55. Metzker, M.L. (2010) Sequencing technologies-the next generation. Nat. Rev. Genet., 11, 31-46.
56. Rosenberg, N.A. (2006) Standardized subsets of the HGDP-CEPH Human Genome Diversity Cell Line Panel, accounting for atypical and duplicated samples and pairs of close relatives. Ann. Hum. Genet., 70, 841-847.
57. Scheet, P. and Stephens, M. (2006) A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am. J. Hum. Genet., 78, 629-644.
58. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.
59. Hemminger, B.M., Saelim, B. and Sullivan, P.F. (2006) TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics, 22, 626-627.
60. Pruitt, K.D., Tatusova, T. and Maglott, D.R. (2007) NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res., 35, D61-D65.
61. Excoffier, L., Laval, G. and Schneider, S. (2005) Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol. Bioinform. Online, 1, 47-50.
62. Weir, B.S. and Cockerham, C.C. (1984) Estimating F-statistics for the analysis of population structure. Evolution, 38, 1358-1370.
63. Coto, E., Tavira, B., Marin, R., Ortega, F., Lopez-Larrea, C., Ruiz-Ortega, M., Ortiz, A., Diaz, M., Corao, A.I., Alonso, B. et al. (2010) Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem. Biophys. Res. Commun., 397, 576-579.
64. Tojcic, J., Benoit-Biancamano, M.O., Court, M.H., Straka, R.J., Caron, P. and Guillemette, C. (2009) In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab. Dispos., 37, 2236-2243.
65. Nielsen, R., Williamson, S., Kim, Y., Hubisz, M.J., Clark, A.G. and Bustamante, C. (2005) Genomic scans for selective sweeps using SNP data. Genome Res., 15, 1566-1575.
66. Kim, W.J., Lee, J.H., Yi, J., Cho, Y.J., Heo, K., Lee, S.H., Kim, S.W., Kim, M.K., Kim, K.H., In Lee, B. et al. (2010) A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics, 20, 249-256.
67. Tomlinson, B., Hu, M., Lee, V.W., Lui, S.S., Chu, T.T., Poon, E.W., Ko, G.T., Baum, L., Tam, L.S. and Li, E.K. (2010) ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther., 87, 558-562.
68. Agundez, J.A., Garcia-Martin, E. and Martinez, C. (2009) Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol., 5, 607-620.
69. Ross, K.A., Bigham, A.W., Edwards, M., Gozdzik, A., Suarez-Kurtz, G. and Parra, E.J. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet., 55, 582-589.
70. Kelemen, L.E., Goodman, M.T., McGuire, V., Rossing, M.A., Webb, P.M., Kobel, M., Anton-Culver, H., Beesley, J., Berchuck, A., Brar, S. et al. (2010) Genetic variation in TYMSin the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev., 19, 1822-1830.
71. Kim, H.N., Kim, N.Y., Yu, L., Kim, Y.K., Lee, I.K., Yang, D.H., Lee, J.J., Shin, M.H., Park, K.S., Choi, J.S. et al. (2009) Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma. Am. J. Hematol., 84, 821-825.
72. Szental, J.A., Baird, P.N., Richardson, A.J., Islam, F.M., Scholl, H.P., Charbel Issa, P., Holz, F.G., Gillies, M. and Guymer, R.H. (2010) Analysis of glutathione S-transferase Pi isoform (GSTP1) single-nucleotide polymorphisms and macular telangiectasia type 2. Int. Ophthalmol, DOI: 10.1007/s10792-010-9374-z.
73. Agundez, J.A., Golka, K., Martinez, C., Selinski, S., Blaszkewicz, M. and Garcia-Martin, E. (2008) Unraveling ambiguous NAT2 genotyping data. Clin. Chem., 54, 1390-1394.
74. Pinsonneault, J., Nielsen, C.U. and Sadee, W. (2004) Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther., 311, 1088-1096.
75. Kim, D.H., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H.A. and Lipton, J.H. (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res., 15, 4750-4758.
76. Sallinen, R., Kaunisto, M.A., Forsblom, C., Thomas, M., Fagerudd, J., Pettersson-Fernholm, K., Groop, P.H. and Wessman, M. (2010) Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension. Ann. Med., 42, 296-304.
77. Vladutiu, G.D. and Isackson, P.J. (2009) SLCO1B1 variants and statin-induced myopathy. N. Engl. J. Med., 360, 304.
78. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y. and Nakamura, Y. (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci., 99, 967-972.
79. Jeannesson, E., Siest, G., Bastien, B., Albertini, L., Aslanidis, C., Schmitz, G. and Visvikis-Siest, S. (2009) Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin. Chim. Acta, 403, 198-202.
80. Sookoian, S., Castano, G., Gianotti, T.F., Gemma, C. and Pirola, C.J. (2009) Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem., 20, 765-770.
81. Kwara, A., Lartey, M., Sagoe, K.W., Kenu, E. and Court, M.H. (2009) CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS, 23, 2101-2106.
82. Carr, D.F., la Porte, C.J., Pirmohamed, M., Owen, A. and Cortes, C.P. (2010) Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J. Antimicrob. Chemother., 65, 1889-1893.
83. Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., Damcott, C.M., Pakyz, R., Tantry, U.S., Gibson, Q. et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302, 849-857.